Specify a stock or a cryptocurrency in the search bar to get a summary
Loncar Cancer Immunotherapy ETF
CNCRLoncar Cancer Immunotherapy ETF, a constituent of the ETF, is listed on the NASDAQ. Its market capitalization stands at 13 111 840 USD. Over the past year, it has generated a yield of +34.26 %. The fund's net expense ratio, a critical measure of operational efficiency, is recorded at 0.79 %. A significant allocation in cash assets underscores its liquidity position and risk management strategy. Turning to technical indicators, they offer a granular perspective on the fund's market behavior, historical trends, and potential forward momentum. For further metrics, refer to www.LoncarFunds.com. For an in-depth analysis get premium access.